Key result
Cyclosporine A withdrawal fails to improve carotid distensibility or FMD versus continuation in renal transplant recipients.
Why the study?
Does withdrawal of cyclosporine A improve arterial distensibility and endothelial function in renal transplant recipients?
RCT (n=24)
randomized
Does withdrawal of cyclosporine A improve arterial distensibility and endothelial function in renal transplant recipients?
Withdrawal of cyclosporine A does not appear to improve endothelial dysfunction or large artery distensibility in renal transplant recipients.
Withdrawal of cyclosporine A offers no vascular benefit in renal transplant recipients; challenges rationale for minimization to improve endothelial function.
Whether withdrawal of calcineurin inhibitors has a beneficial effect on disturbed endothelial function and large artery distensibility in renal transplant recipients is not clear. We studied the effects of cyclosporine A (CsA) withdrawal on arterial compliance and endothelium-dependent flow-mediated vasodilatation (FMD) in a prospective, randomized trial; 24 renal transplant recipients receiving mycophenolate mofetil were randomized to withdrawal (n=12) or continuation of CsA (n=12). At baseline and after 6 months, carotid and brachial artery distensibility coefficients and brachial FMD were measured. Brachial distensibility coefficients increased in both groups (withdrawal: 11.1+/-1-14.9+/-2 10(-3)/kPa, continuation: 10.7+/-1-15.2+/-3 10(-3)/kPa, P<0.05, respectively). However, there was no significant effect of treatment on carotid artery distensibility coefficients, FMD, or graft function. Withdrawal of CsA failed to improve carotid artery distensibility or brachial FMD in patients after renal transplantation. Our data indicate that CsA treatment does not contribute significantly to endothelial dysfunction observed in renal transplant recipients.
No takes yet. Share an insight, caveat, or question.
Kosch et al. (2003) conducted an RCT in Renal transplant (n=24). Cyclosporine A (CsA) withdrawal vs. Continuation of CsA was evaluated on Carotid and brachial artery distensibility coefficients and brachial flow-mediated vasodilatation (FMD). Withdrawal of cyclosporine A failed to improve carotid artery distensibility or brachial flow-mediated vasodilatation compared to continuation in renal transplant recipients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: